Equities

Salarius Pharmaceuticals Inc

Salarius Pharmaceuticals Inc

Actions
  • Price (EUR)0.00
  • Today's Change0.00 / -100.00%
  • Shares traded--
  • 1 Year change-100.00%
  • Beta--
Data delayed at least 15 minutes, as of Jun 17 2024 07:31 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments5.901229
Total Receivables, Net01.610
Total Inventory------
Prepaid expenses0.620.800.95
Other current assets, total------
Total current assets6.521530
Property, plant & equipment, net----0.01
Goodwill, net--08.87
Intangibles, net------
Long term investments------
Note receivable - long term--01.61
Other long term assets0.070.130.19
Total assets6.591541
LIABILITIES
Accounts payable0.602.861.54
Accrued expenses0.411.410.55
Notes payable/short-term debt0.2900
Current portion long-term debt/capital leases------
Other current liabilities, total----0.01
Total current liabilities1.304.272.11
Total long term debt000
Total debt0.2900
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities1.304.272.11
SHAREHOLDERS EQUITY
Common stock0.000.000.00
Additional paid-in capital827471
Retained earnings (accumulated deficit)(76)(64)(32)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity5.291039
Total liabilities & shareholders' equity6.591541
Total common shares outstanding0.490.280.23
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.